# ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion.

> **NCT07680673** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Encellin** · enrollment: 10 (estimated)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DEVICE:** ENCRT-103-hPI encompasses the ENC-103 device, which will be implanted once loaded with primary islet cargo.

## Key facts

- **NCT ID:** NCT07680673
- **Lead sponsor:** Encellin
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2027-01-06
- **Primary completion:** 2028-07-06
- **Final completion:** 2029-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07680673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07680673, "ENCRT-103-hPI: Evaluation of an Immune-protected ENCRT-103-hPI Containing Primary Human Islets in Adults With Type 1 Diabetes, With and Without Standard-of-care Portal Vein Islet Infusion.". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07680673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*